FR2471190A1 - THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR - Google Patents
THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR Download PDFInfo
- Publication number
- FR2471190A1 FR2471190A1 FR7930380A FR7930380A FR2471190A1 FR 2471190 A1 FR2471190 A1 FR 2471190A1 FR 7930380 A FR7930380 A FR 7930380A FR 7930380 A FR7930380 A FR 7930380A FR 2471190 A1 FR2471190 A1 FR 2471190A1
- Authority
- FR
- France
- Prior art keywords
- weight
- parts
- antitussive
- cough
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 6
- 230000000954 anitussive effect Effects 0.000 title claims description 12
- 229940124584 antitussives Drugs 0.000 title claims description 12
- 239000000739 antihistaminic agent Substances 0.000 title claims description 9
- 230000001387 anti-histamine Effects 0.000 title claims description 8
- 230000002921 anti-spasmodic effect Effects 0.000 title claims description 8
- 239000000812 cholinergic antagonist Substances 0.000 title claims description 8
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 title claims description 5
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 title 1
- 241000173529 Aconitum napellus Species 0.000 claims abstract description 13
- 229940023019 aconite Drugs 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 229940098465 tincture Drugs 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims abstract description 7
- 229960004578 ethylmorphine Drugs 0.000 claims abstract description 7
- 229960003291 chlorphenamine Drugs 0.000 claims abstract description 6
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims abstract description 6
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229920002678 cellulose Polymers 0.000 claims abstract description 3
- 239000001913 cellulose Substances 0.000 claims abstract description 3
- 239000002562 thickening agent Substances 0.000 claims abstract description 3
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims description 11
- 206010011224 Cough Diseases 0.000 claims description 9
- 239000003172 expectorant agent Substances 0.000 claims description 9
- 230000003419 expectorant effect Effects 0.000 claims description 9
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 6
- 229920003086 cellulose ether Polymers 0.000 claims description 6
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- ZPPBASOODYCKDP-YZZSNFJZSA-N (4r,4ar,7s,7ar,12bs)-9-ethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrochloride Chemical compound Cl.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC ZPPBASOODYCKDP-YZZSNFJZSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 description 10
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- -1 ethyl orthoformate Chemical compound 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
- FXHGNNYOXDWQFY-UHFFFAOYSA-N ethyl (7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl)methanesulfonate Chemical compound C1CC2CC(=O)C1(CS(=O)(=O)OCC)C2(C)C FXHGNNYOXDWQFY-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRESENTE INVENTION A TRAIT A UNE COMPOSITION THERAPEUTIQUE SANS SUCRE, UTILE DANS LE TRAITEMENT DE LA TOUX, ET RENFERMANT: A.4,5 A 8,5PARTIES EN POIDS D'UN COMPOSE CHOISI PARMI L'ETHYLMORPHINE ET SES SELS; B.10 A 70PARTIES EN POIDS DE TEINTURE D'ACONIT; C.1 A 3PARTIES EN POIDS D'UN COMPOSE CHOISI PARMI LA CHLORPHENIRAMINE ET SES SELS; ET D.10 A 30PARTIES EN POIDS DE GLYCEROGAIACOL. CETTE COMPOSITION FORMULEE AVEC UN AGENT EPAISSISSANT DU TYPE ETHER DE CELLULOSE ET DE L'EAU EST ADMINISTRABLE PAR VOIE ORALE.THE PRESENT INVENTION RELATES TO A THERAPEUTIC COMPOSITION WITHOUT SUGAR, USEFUL IN THE TREATMENT OF Cough, AND CONTAINING: A 4.5 TO 8.5 PARTS BY WEIGHT OF A COMPOUND CHOSEN FROM ETHYLMORPHINE AND ITS SALTS; B.10 TO 70PARTMENTS BY WEIGHT OF ACONITE TINCTURE; C.1 HAS 3PARTS BY WEIGHT OF A COMPOUND CHOSEN FROM CHLORPHENIRAMINE AND ITS SALTS; AND D.10 TO 30 PARTS BY WEIGHT OF GLYCEROGAIACOL. THIS COMPOSITION FORMULATED WITH A THICKENING AGENT OF THE ETHER TYPE OF CELLULOSE AND WATER IS ADMINISTRABLE ORAL.
Description
24711 9024711 90
Composition thérapeutique, utile dans le traitement de la toux, comprenant un moyen antitussif, un moyen antispasmodique, un moyen Therapeutic composition, useful in the treatment of cough, comprising antitussive means, antispasmodic means, means
antihistaminique et un moyen expectorant. antihistamine and an expectorant means.
La présenté invention a trait, en tant que produit industriel nouveau et utile en thérapeutique dans le traitement de The present invention relates, as a new industrial product and useful in therapeutics in the treatment of
la toux, à une composition comprenant en association un moyen anti- coughing, to a composition comprising in combination an ant
tussif, un moyen antispasmodique, un moyen antihistaminique et un moyen expectorant. On sait que dans le passé on a commercialisé des spécialités pour le traitement de la toux comprenant en association tussif, antispasmodic means, antihistamine and expectorant means. It is known that in the past there have been commercialized specialties for the treatment of cough comprising in association
une ou plusieurs substances antitussives, antispasmodiques, anti- one or more antitussive substances, antispasmodic, ant
histaminiques, expectorantes et/ou antiseptiques. Parmi les substances antitussives qui ont été utilisées on peut mentionner la codéine, la Néthyl-3,4-dihydroxynoréphédrine (ou dioxyéthédrine) et la teinture histamine, expectorant and / or antiseptic. Of the antitussive substances that have been used, mention may be made of codeine, N-3,4-dihydroxynorephedrine (or dioxyethedrine) and dyeing.
d'aconit, cette dernière ayant des propriétés antitussives et anti- aconite, the latter having antitussive and anti-
spasmodiques. Parmi les substances antihistaminiques, on peut citer spasmodic. Among the antihistamine substances, mention may be made of
la prométhazine et parmi les substances expectorantes et/ou anti- promethazine and among expectorant and / or
septiques, l'hydroxyquinoléine, le sulfogalacol. De telles spécialités présentent l'inconvénient de contenir du sucre, car conditionnées septic drugs, hydroxyquinoline, sulfogalacol. Such specialties have the disadvantage of containing sugar, because packaged
sous forme de sirop.in the form of syrup.
Pour traiter la toux de patients (notamment les diabétiques) ne devant pas ou ne voulant pas prendre de sucre, des To treat the coughing of patients (especially diabetics) not having or wanting to take sugar,
solutions techniques différentes de la solution sirop rappelée ci- technical solutions different from the syrup solution mentioned
dessus et n'impliquant pas l'utilisation de sucre ont été préconisées, en particulier celles qui consistent à administrer un principe actif above and not involving the use of sugar have been advocated, in particular those of administering an active ingredient
antitussif tel que l'orthoformiate d'éthyle, la N-(p-acétyloxime- antitussive such as ethyl orthoformate, N- (p-acetyloxime)
phénoxy-acétyl)-morpholine, la N-(p-acétyloxime-phénoxy-acétyl)-pipé- phenoxy-acetyl) -morpholine, N- (p-acetyloxime-phenoxy-acetyl) -piperazine
ridine et les analogues de ces deux dernières du type p-oximephénoxy- ridine and the analogs of the latter two of the p-oximephenox-
alkylamide décrits dans les brevets français n0 69.39954 et alkylamide described in French Patent Nos. 69.39954 and
72.36165, sous forme de comprimés, gélules ou suppositoires. 72.36165, in the form of tablets, capsules or suppositories.
Selon l'invention, on préconise une autre solution technique qui consiste à administrer une association particulière According to the invention, it is recommended another technical solution which consists in administering a particular association
de moyens antitussif, antispasmodique, antihistaminique et expectorant. antitussive, antispasmodic, antihistaminic and expectorant means.
Un des buts de l'invention est de proposer une associa- One of the aims of the invention is to propose an association
tion synergétique pour le traitement de la toux. synergetic treatment for the treatment of cough.
Un autre des buts de l'invention est de proposer une association de moyens antitussif, antispasmodique, antihistaminique et expectorant, sous forme de solution buvable pour le traitement de la toux, ladite solution buvable étant sirupeuse,c'est-à-dire Another object of the invention is to propose a combination of antitussive, antispasmodic, antihistaminic and expectorant means, in the form of an oral solution for the treatment of cough, said oral solution being syrupy, that is to say
ayant l'aspect d'un sirop, mais ne comportant pas de sucre. having the appearance of a syrup, but not containing sugar.
Un autre des buts de l'invention est de préparer une associa- Another object of the invention is to prepare an associa-
tion exempte de sodium.sodium free.
La composition selon l'invention est caractérisée en ce qu'el- le renverme, en association avec un excipient physiologiquement The composition according to the invention is characterized in that it reverses, in association with a physiologically excipient.
acceptable,acceptable,
a) 4,5 à 8,5 parties en poids d'un composé choisi parmi l'éthylmorphine et ses sels; b) 10 à 70 parties en poids de teinture d'aconit; c) I à 3 parties en poids d'un composé choisi parmi la chlorphéniramine et ses sels; et a) 4.5 to 8.5 parts by weight of a compound selected from ethylmorphine and its salts; b) 10 to 70 parts by weight of aconite dye; c) I to 3 parts by weight of a compound selected from chlorpheniramine and its salts; and
d) 10 à 30 parties en poids de glycérogalacol. d) 10 to 30 parts by weight of glycerogalacol.
La substance a) agit en tant que produit antitussif. Parmi les sels utilisables on peut mentionner le chlorhydrate,lecamphosulfonate, The substance a) acts as an antitussive product. Among the salts that may be used, mention may be made of the hydrochloride, lecamphosulphonate,
ou le méthyliodure, les sels préférés étant le chlorhydrate (codé- or methyliodide, the preferred salts being the hydrochloride (coded as
thyline) et le camphosulfonate.thyline) and camphosulphonate.
La substance b) agit comme antitussif et antispasmodique.Elle Substance b) acts as antitussive and antispasmodic.It
est préparée selon le procédé d'extraction décrit dans la pharmacopée. is prepared according to the extraction method described in the pharmacopoeia.
La substance c), c'est-à-dire la chlorphéniramine ou 2-/-4- Substance (c), that is, chlorpheniramine or 2 - / - 4-
chloro- v-(2-diméthylaminoéthyl)-benzyl/-pyridine et ses sels, in- chlorov (2-dimethylaminoethyl) benzyl / pyridine and its salts,
tervient en tant qu'agent antihistaminique.Le sel préféré selon l'in- as an antihistamine agent.The preferred salt according to
vention est le maleate.vention is maleate.
La substance d) également connue sous les nomenclatures de 3-(ométhoxyphénoxy)-1,2-propanediol et de gaïacol glycéryl éther agit Substance d) also known under the nomenclature of 3- (omethoxyphenoxy) -1,2-propanediol and guaiacol glyceryl ether acts
en tant que substance expectorante.as an expectorant substance.
De façon avantageuse on préparera une composition aqueuse buvable en associant les substances a)-d) à un agent épaississant e) choisi parmi l'ensemble des éthers de cellulose tels que,notamment, Advantageously, an aqueous drinkable composition will be prepared by combining the substances a) -d) with a thickening agent e) chosen from the group of cellulose ethers such as, in particular,
les méthylcellulose,éthylcellulose, hydroxyéthyl-cellulose, hydroxy- methylcellulose, ethylcellulose, hydroxyethyl cellulose, hydroxyl
propyl-méthylcellulose,carboxyméthylcellulose, et de l'eau déminéra- propyl methylcellulose, carboxymethylcellulose, and demineral water.
lisée ou distillée.La composition selon l'invention comprendra alors: a) 4,5 à 8,5 parties en poids d'un composé choisi parmi l'éthylmorphine et ses sels; b) 10 à 70 parties en poids de teinture d'aconit; c) 1 à 3 parties en poids d'un composé choisi parmi la chlorphéniramine et ses sels; d) 10 à 30 parties en poids de glycérogalacol; et The composition of the invention will then comprise: a) 4.5 to 8.5 parts by weight of a compound selected from ethylmorphine and its salts; b) 10 to 70 parts by weight of aconite dye; c) 1 to 3 parts by weight of a compound selected from chlorpheniramine and its salts; d) 10 to 30 parts by weight of glycerogalacol; and
e) 30 à 70 parties en poids d'éther de cellulose. e) 30 to 70 parts by weight of cellulose ether.
Le moyen e) appartenant à la famille des éthers de cellulose permet d'obtenir un produit final sirupeux et transparent analogue aux sirops mais exempt de sucre. Les substances e) préférées sont l'hydroxyéthylcellulose, la méthylcellulose et leurs mélanges. Le meilleur mode de mise en oeuvre de l'inaeti.on consiste à administrer une composition aqueuse buvable (A):C; la formulation suivante: The means e) belonging to the family of cellulose ethers makes it possible to obtain a syrupy and transparent final product similar to syrups but without sugar. The preferred substances e) are hydroxyethylcellulose, methylcellulose and mixtures thereof. The best mode of implementation of inaeti.on is to administer an aqueous drinkable composition (A): C; the following wording:
COMPOSITION ACOMPOSITION A
(i) codéthyline (chlorhydrate d!éthy1marphine)i 45 à 85 mg (ii) teinture d'aconit 100 à 700 mg (iii} maléate de chlorphéniramine 10 a 30 mg (iv) glycérogalacol 100 à 300 mg (v) éther de cellulose 300 a 700 mg (vi) eau déminéralisée qsp 100 ml Les essais cliniques ont mis en évidence les propriétéY synergétiques de la composition A et en particulier des compositions des exemples 1 à 4, ci-après. On a en effet constaté chez l'homme que la composition A était, vis-à-vis de la toux, 30 à 100 % plus (i) codethylamine (ethylamine hydrochloride) 45 to 85 mg (ii) tincture of aconite 100 to 700 mg (iii) chlorpheniramine maleate 10 to 30 mg (iv) glycerogalacol 100 to 300 mg (v) cellulose ether 300 to 700 mg (vi) demineralised water qs 100 ml Clinical trials have demonstrated the synergistic properties of composition A and in particular the compositions of Examples 1 to 4, hereinafter. that the composition A was, with respect to the cough, 30 to 100% more
efficace que la codéthyline seule, l'aasociation codéthyline - effective than codethyline alone, codethylamine aasociation -
teinture d'aconit et l'association codéthyline - teinture d'aconit - tincture of aconite and the combination of codethylamine and aconite tincture
maléate de chlorphéniramine.chlorpheniramine maleate.
La posologie recommandée est de trois prises par jour, The recommended dosage is three times daily,
de 10 à 15 ml chacune,de composition A pendant 3 jours. 10 to 15 ml each, composition A for 3 days.
Les exemples qui suivent, nullement limitatifs,ont été The following examples, which are in no way limiting, have been
donnés à titre d'illustration.given as an illustration.
Exemple 1Example 1
Selon la formulation de la composition A on prépare une composition aqueuse buvable ayant la formulation suivante: 30. codéthyline 65 mg teinture d'aconit 500 mg maléate de chlorphéniramine 20 mg glycérogalacol 300 mg hydroxyéthylcellulose 500 mg 35. eau déminéralisée qsp 100 ml According to the formulation of the composition A, an aqueous drinkable composition is prepared having the following formulation: 30. codethyline 65 mg tincture of aconite 500 mg chlorpheniramine maleate 20 mg glycerogalacol 300 mg hydroxyethylcellulose 500 mg 35. demineralized water qs 100 ml
Le cas échéant, on peut introduire dans cette formu- Where appropriate, it may be introduced in this formu-
lation un colorant et un arSme.a dye and arsen.
Exemple 2Example 2
On prépare comme à l'exemple 1, une composition aqueuse buvable, en remplaçant les 500 mg d'hydroxyéthyl- As in Example 1, an aqueous drinkable composition is prepared, replacing the 500 mg of hydroxyethyl
cellulose de l'exemple 1, par un mélange de 200 mg d'hydroxy- cellulose of Example 1, with a mixture of 200 mg of hydroxypropyl
éthylcellulose et de 300 mg de méthylcellulose. ethylcellulose and 300 mg of methylcellulose.
Exemple 3Example 3
On prépare comme à l'exemple 1, une composition aqueuse buvable ayant la formulation suivante: codéthyline 50 mg teinture d'aconit 520 mg maléate de chlorphéniramine 25 mg glycérogaiacol 300 mg 15. méthylcellulose 600 mg eau déminéralisée qsp 100 ml A drinkable aqueous composition having the following formulation is prepared as in Example 1: codethylamine 50 mg tincture of aconite 520 mg maleate of chlorpheniramine 25 mg glycerogaiacol 300 mg 15. methylcellulose 600 mg demineralized water qs 100 ml
Exemple 4Example 4
aqueuse buvable On prépare comme à l'exemple 1, ayant la formulation suivante: aqueous drinkable is prepared as in Example 1, having the following formulation:
camphosulfonate d'éthyl-ethyl camphorsulphonate
morphine teinture d'aconit maléate de chlorphéniramine glycérogalacol: hydroxyéthylcellulose eau déminéralisée une composition mg 500 mg mg mg 500 mg morphine tincture of aconite chlorpheniramine maleate glycerogalacol: hydroxyethylcellulose demineralized water a composition mg 500 mg mg mg 500 mg
qsp 100 ml.qsp 100 ml.
Claims (4)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7930380A FR2471190A1 (en) | 1979-12-11 | 1979-12-11 | THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR |
| BE2/58895A BE886573A (en) | 1979-12-11 | 1980-12-10 | THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF Cough COMPRISING AN ANTI-CUSHIONING MEANS, AN ANTISPASMODIC MEANS AND AN EXPECTORING MEANS |
| IT8068888A IT8068888A0 (en) | 1979-12-11 | 1980-12-11 | ANTICOUGH THERAPEUTIC COMPOSITION INCLUDING AN ANTICOUGH AGENT, AN ANTISPASTIC AGENT AND AN EXPECTORANT AGENT |
| GB8039718A GB2064959B (en) | 1979-12-11 | 1980-12-11 | Pharmaceutical anti-tussive composition comprising ethylmorphine aconite tincture and glyceroguaiacol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7930380A FR2471190A1 (en) | 1979-12-11 | 1979-12-11 | THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2471190A1 true FR2471190A1 (en) | 1981-06-19 |
| FR2471190B1 FR2471190B1 (en) | 1983-04-08 |
Family
ID=9232652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7930380A Granted FR2471190A1 (en) | 1979-12-11 | 1979-12-11 | THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE886573A (en) |
| FR (1) | FR2471190A1 (en) |
| GB (1) | GB2064959B (en) |
| IT (1) | IT8068888A0 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1465347A (en) * | 1973-06-20 | 1977-02-23 | Fisons Corp | Composition |
-
1979
- 1979-12-11 FR FR7930380A patent/FR2471190A1/en active Granted
-
1980
- 1980-12-10 BE BE2/58895A patent/BE886573A/en not_active IP Right Cessation
- 1980-12-11 GB GB8039718A patent/GB2064959B/en not_active Expired
- 1980-12-11 IT IT8068888A patent/IT8068888A0/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1465347A (en) * | 1973-06-20 | 1977-02-23 | Fisons Corp | Composition |
Non-Patent Citations (3)
| Title |
|---|
| EXBK/61 * |
| EXBK/66 * |
| EXBK/77 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IT8068888A0 (en) | 1980-12-11 |
| GB2064959A (en) | 1981-06-24 |
| GB2064959B (en) | 1983-12-14 |
| BE886573A (en) | 1981-06-10 |
| FR2471190B1 (en) | 1983-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW589174B (en) | Agent for treating high-risk impaired glucose tolerance | |
| US6287597B1 (en) | Antihistaminic/decongestant compositions | |
| JP4445590B2 (en) | Oral liquid composition containing paroxetine-resin | |
| US20040234593A1 (en) | Diphenhydramine tannate compositions and methods of use | |
| HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| EP0283369B1 (en) | Use of Metformin in the preparation of medicaments | |
| KR20100135316A (en) | Liquid formulation for deferiprone with palatable taste | |
| JPH04159223A (en) | Emetocathartic composition | |
| JP2004534094A (en) | Composition effective for hangover and use therefor | |
| JPS6256426A (en) | Medicinal composition for treating human malaria | |
| HU225657B1 (en) | Process for producing flavano-lignane compositions of improved release and absorption, compositions produced this way find use of them for producing pharmaceutical compositions | |
| FR2482860A1 (en) | COMPOSITION AND PREPARATION OF AN ANTIMICROBIAL AGENT | |
| EP1543826B1 (en) | Concentrated aqueous solution of ambroxol | |
| RU2261098C2 (en) | Mirtazapine-containing orally decomposing composition | |
| WO1999048501A9 (en) | Voacamine as anti-malarial agent and anti-malarial agent containing voacamine | |
| FR2912654A1 (en) | Medicament composition, useful in treating spasmodic diseases e.g. spastic colitis and dysmenorrhea, comprises phloroglucinol and paracetamol formulated together/separately for combined, simultaneous/separate use of antispasmodic therapy | |
| FR2471190A1 (en) | THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR | |
| US20170020946A1 (en) | Analgesic compositions and methods of use | |
| JPH10504279A (en) | Pharmaceutical compositions for prevention and / or treatment of viral infections and possibly inflammation and methods of treating them | |
| JP3150642B2 (en) | Novel anticonvulsant and anti-inflammatory compositions and methods for their production | |
| AU2003217704A1 (en) | Diphenhydramine tannate compositions and methods of use | |
| RU2619736C2 (en) | Capsules for complex treatment of urinary system diseases | |
| RU2426531C1 (en) | Liquid water pharmaceutical composition of ambroxol and pharmaceutical preparation based on it, intended for treating diseases of respiratory ways with formation of viscous sputum (versions) | |
| BE1007586A3 (en) | Pharmaceutical products. | |
| JP2876224B2 (en) | New whitening agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |